In contrast, IL-10 treatment has surprisingly demonstrated antitumor efficacy, as shown with PEGylated IL-10, which induced the expression of IFNγ and granzymes in the tumor and induced the CD8+ T cell-mediated rejection of breast cancer models in mice. The gene discussed is IL10; the disease is breast carcinoma.